POISE-2: A large, international, placebo-controlled, factorial trial to assess the impact of clonidine and aspirin in patients undergoing noncardiac surgery who are at risk of a perioperative cardiovascular event

POISE-2：一项大型国际安慰剂对照析因试验，旨在评估可乐定和阿司匹林对接受非心脏手术且有围手术期心血管事件风险的患者的影响

• 批准号: nhmrc : 1004149
• 负责人: Prof Clara Chow
• 金额: $ 79.88万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/poise-2-large-cardiovascular-event/109003
• 关键词: POISE; large; international; placebo; controlled

At least 5 million patients annually worldwide suffer a heart attack or die after noncardiac surgery. Despite the magnitude of this problem, there are no good treatments to prevent these complications. Previous studies suggest that the drugs clonidine and aspirin may minimize the risk of heart attack after surgery. The POISE-2 trial will study 10,000 patients having noncardiac surgery to determine if clonidine and aspirin improve outcomes. This trial will influence the treatment of patients having surgery around the world.

全世界每年至少有500万患者在非心脏手术后心脏病发作或死亡。尽管这个问题很严重，但没有很好的治疗方法来预防这些并发症。以前的研究表明，可乐定和阿司匹林可以降低手术后心脏病发作的风险。POISE-2试验将研究10，000名接受非心脏手术的患者，以确定可乐定和阿司匹林是否能改善预后。这项试验将影响世界各地手术患者的治疗。